Khalid Rauf, MD
Sleep Medicine · Madera, CANPI 1700802709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.
Across 355 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Grifols USA, LLC$1K
- Harmony Biosciences LLC$775
- Boehringer Ingelheim$605
- AstraZeneca$560
- Jazz Pharmaceuticals Inc.$499
- plus $2K from 28 others
What the payments were for
- Consulting fees$2003%
- Food & beverage$6,76292%
- Education$3935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 120 | $1,494 |
| Grifols USA, LLC | 42 | $1,004 |
| Harmony Biosciences LLC | 21 | $775 |
| Boehringer Ingelheim | 30 | $605 |
| AstraZeneca | 33 | $560 |
| Jazz Pharmaceuticals Inc. | 11 | $499 |
| Bayer | 12 | $387 |
| United Therapeutics Corporation | 7 | $318 |
| Regeneron Healthcare Solutions, Inc. | 6 | $182 |
| Sunovion Pharmaceuticals Inc. | 14 | $173 |
| Verona Pharma, Inc. | 6 | $169 |
| Insmed, Inc. | 5 | $136 |
| Advanced Respiratory, Inc | 4 | $125 |
| Philips North America LLC | 7 | $124 |
| Sanofi | 4 | $103 |
| Alnylam Pharmaceuticals Inc. | 5 | $103 |
| Fisher & Paykel Healthcare Inc | 4 | $84 |
| Mylan Specialty L.p. | 3 | $61 |
| Olympus America Inc. | 1 | $49 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $40 |
| Exact Sciences | 1 | $26 |
| Abbott | 1 | $25 |
| Resmed Corp | 1 | $25 |
| Novo Nordisk | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Medtronic | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,356 in reported general payments places this provider in the 80th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 416 | $322,018 |
| XywavSodium,calcium,mag,pot Oxybate | 13 | $255,715 |
| OfevNintedanib Esylate | 15 | $170,601 |
| Breo ElliptaFluticasone/Vilanterol | 279 | $117,315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 754 | $24,142 |
| Spiriva RespimatTiotropium Bromide | 34 | $20,875 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $16,147 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,136 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 99 | $13,204 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $12,382 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $11,761 |
| JardianceEmpagliflozin | 16 | $11,536 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $7,992 |
| BreynaBudesonide/Formoterol Fumarate | 43 | $7,954 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $6,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,494 | $463,472733 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Jardiance | $605 | $214,77487 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $560 | $28,51874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 200 sleep medicine providers in California.
Other sleep medicine in Madera
- David SuhrbierMadera$12K
- Tabish NazMadera$5K
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.1M
- Atul MalhotraSan Diego$771K
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Sam KashaniSanta Monica$221K
- Emmanuel MignotStanford$135K
- Jerome HesterPalo Alto$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.